1. Paris-Saclay University, Faculty of Medecine, Le Kremlin-Bicêtre, France;
2. INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies, Marie Lannelongue Hospital, Le Plessis-Robinson, France;
3. Paris Cité University, CNRS, INSERM, Institut Necker Enfants Malades-INEM, Paris, France;
4. Department of Physiology and
5. Department of Pharmacology, University of Vermont, Burlington, Vermont;
6. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain;
7. Genetics Department, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France;
8. INSERM US24/CNRS UAR3633, Proteomic Platform Necker, Université Paris Cité-Federative Research Structure Necker, Paris, France;
9. Gly-CRRET Research Unit 4397, Paris-Est Créteil University, Créteil, France;
10. Department of Pharmacology and Toxicology, Faculty of Medicine, University Complutense of Madrid, Madrid, Spain;
11. Ciber Enfermedades Respiratorias (CIBERES), Madrid, Spain;
12. Paris-Saclay University, Faculty of Pharmacy, Orsay, France;
13. Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Bicêtre Hospital, Le Kremlin-Bicêtre, France;
14. Paris-Saclay University, INRAE, AgroparisTech, GABI, Jouy-en-Josas, France;
15. Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Groupe Hospitalier Paris Saint-Joseph-Marie Lannelongue Hospital, Le Plessis-Robinson, France.